Apply for Grants
The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Novel PET Tracer Development Program, 2023Development of a PET Tracer for Imaging of Neuroinflammation in Parkinson’s Disease
Study Rationale: Neuroinflammation plays a key role in the degeneration of dopamine-producing neurons and is critical in the pathogenesis of Parkinson’s disease (PD). Positron Emission Tomography (PET...
-
Translational Pipeline Program, 2023Evaluation of Glunomab, a Novel Immunotherapy for the Treatment of Parkinson’s Disease
Study Rationale: Glunomab is a monoclonal antibody that inhibits a toxic interaction between two proteins recently determined to be involved in the pathology of Parkinson’s disease (PD). Because its...
-
Translational Pipeline Program, 2023Using Cellular Approaches to Deep Brain Stimulation to Revert Gait Disorders
Study Rationale: Gait deficits in Parkinson’s disease (PD) are not well controlled with existing therapeutic strategies. Episodic gait deficits such as freezing of gait are particularly debilitating...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Effects of Chemical Modifications on Aggregation of Alpha-synuclein
Study Rationale: Evidence suggests that alpha-synuclein causes the death of neurons in the brains of people with Parkinson’s disease (PD) by forming clusters (or ‘aggregates’) on the surface of...
-
Biomarkers to Support Therapeutic Trials Program, 2023Blood Test for Stratifying People with Parkinson’s Disease based on Extracellular Vesicles Derived from Neurons
Study Rationale: Parkinson’s disease (PD) and other synucleinopathies are diagnosed based on symptoms and clinical testing. However, these tests can be inaccurate, and postmortem analysis reveals that...
-
Research Grant, 2023Allogeneic Bone marrow-derived Mesenchymal Stem Cells as a disease-modifying therapy for idiopathic Parkinson’s disease: Phase IIa double-blind, randomized controlled trial
Study Rationale: Chronic neuroinflammation plays a critical role in the development and progression of Parkinson’s disease (PD). Neuroinflammation damages the brain microenvironment, disrupts the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.